NeuroSense Therapeutics Quote - NRSN | ADVFN

S&P TSX Capped Composite...

US Dollar vs CAD

Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

Get Started

Home
Investing
Stocks
USA
NASDAQ
NeuroSense Therapeutics Ltd (NRSN) Share Price

NeuroSense Therapeutics Ltd (NRSN)

1.28

0.01

(0.79%)

Closed September 28 3:00PM

Delayed by 15 minutes

1.28

0.00

(0.00%)

After Hours: 3:00PM

Delayed by 15 minutes

Empower your portfolio: Real-time discussions and actionable trading ideas.

Current Price

1.28

Bid

1.21

Ask

1.33

Volume

64,438

1.25 Day's Range 1.30

0.40 52 Week Range 2.33

Previous Close

1.27

Open

1.30

Last Trade

Last Trade Time

Average Volume (3m)

354,901

Financial Volume

US$ 81,649

VWAP

1.2671

NeuroSense Therapeutics Granted Key U.S. Patent for Novel PrimeC Formulation, its Lead Asset for ALS and Alzheimer's

NeuroSense Therapeutics Granted Key U.S. Patent for Novel PrimeC Formulation, its Lead Asset for ALS and Alzheimer's PR Newswire CAMBRIDGE, Mass., Sept. 24, 2024 The Company's intellectual...

NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule

NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule PR Newswire CAMBRIDGE, Mass., Sept. 24, 2024 CAMBRIDGE, Mass., Sept. 24, 2024 /PRNewswire/ -- NeuroSense Therapeutics...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

NeuroSense Therapeutics Announces Receipt of Nasdaq Minimum Bid Price Notification

NeuroSense Therapeutics Announces Receipt of Nasdaq Minimum Bid Price Notification PR Newswire CAMBRIDGE, Mass., Aug. 30, 2024 CAMBRIDGE, Mass., Aug. 30, 2024 /PRNewswire/ -- NeuroSense...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 424B5 - Prospectus [Rule 424(b)(5)]

NeuroSense Therapeutics Announces Private Placement with Senior Management Participation at Premium to Market Price

NeuroSense Therapeutics Announces Private Placement with Senior Management Participation at Premium to Market Price PR Newswire CAMBRIDGE, Mass., Aug. 7, 2024 CAMBRIDGE, Mass., Aug. 7, 2024...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-0.03	-2.29007633588	1.31	1.35	0.9	249375	1.25023199	CS
4	0.53	70.6666666667	0.75	1.455	0.730001	317561	1.12102414	CS
12	-0.02	-1.53846153846	1.3	1.455	0.512	354901	0.87700332	CS
26	-0.52	-28.8888888889	1.8	2.25	0.512	266772	1.04511227	CS
52	0.515	67.3202614379	0.765	2.33	0.4	424958	1.06029707	CS
156	-3.27	-71.8681318681	4.55	8.18	0.4	1040182	3.44443341	CS
260	-3.27	-71.8681318681	4.55	8.18	0.4	1040182	3.44443341	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
UXINUxin Ltd	US$ 5.145 (81.80%)	46.69M
ONCOOnconetix Inc	US$ 5.92 (76.43%)	34.68M
JFU9F Inc	US$ 2.3101 (76.34%)	2.48M
NANano Labs Ltd	US$ 1.005 (73.31%)	3.34M
CNEYCN Energy Group Inc	US$ 0.9473 (63.36%)	221.89M
ICGIntchains Group Ltd	US$ 4.77 (-43.75%)	2.86M
EDBLEdible Garden AG Inc	US$ 0.288 (-38.09%)	5.79M
DSYBig Tree Cloud Holdings Limited	US$ 2.44 (-28.24%)	416.35k
NVNOenVVeno Medical Corporation	US$ 3.255 (-27.67%)	2.36M
ADTXAditxt Inc	US$ 0.165 (-24.83%)	12.23M
NVDANVIDIA Corporation	US$ 121.40 (-2.13%)	271.06M
XPONExpion360 Inc	US$ 0.0717 (11.34%)	266.01M
CNEYCN Energy Group Inc	US$ 0.9473 (63.36%)	221.89M
TNXPTonix Pharmaceuticals Holding Corporation	US$ 0.1462 (7.03%)	207.04M
SQQQProShares UltraPro Short QQQ	US$ 7.45 (1.78%)	133.67M

runncoach

runncoach 1 month ago

From this evening's 6K. No idea if it's BS or not.
NeuroSense Therapeutics Ltd. (the Company) hereby reports that it is currently in advanced discussions with several multi-billion-dollar pharmaceutical companies regarding a potential strategic partnership for the development and commercialization of its lead drug candidate, PrimeC, for the treatment of Amyotrophic Lateral Sclerosis (ALS).

These discussions, based on non-binding terms, indicate the potential for substantial financial benefits to NeuroSense, including upfront payments, milestone payments and royalty payments as part of an agreement. NeuroSense anticipates receiving terms from these discussions in Q4 2024; however, there can be no assurance that terms will be finalized with any of the pharmaceutical companies, the timing, what would be the final terms, if any, or that a definitive agreement will be reached.

runncoach

runncoach 2 months ago

Money raise with .75 warrants attached fyi. Now we know why the price has remained so low IMO

vein

vein 3 months ago

Thanks much for the insight !

runncoach

runncoach 3 months ago

Who knows? Unless you are trading the stock, real results are a long ways off IMO and that can lead to opportunity cost. If it's a small percentage of a speculative portfolio the current price probably isn't bad. Just depends on your patience level

vein

vein 3 months ago

Why the sell off ?? Thanks in advance!

vein

vein 3 months ago

Seems like a decent entry ?

runncoach

runncoach 3 months ago

The data is good but they'll have to raise money for a P3 so these guys are still a ways off IMO. They've mentioned a potential Biogen partnership last year yet here we stand. I do believe the drug is safe and has a real chance. Timing is everything.

vein

vein 3 months ago

Time to buy now ??? Newbie here! Any thoughts ??

Monksdream

Monksdream 3 months ago

runncoach

runncoach 3 months ago

Great data out. On to P3. Only thing that will likely sustain share price after this rally is partnership IMO.

Awl416

Awl416 3 months ago

runncoach

runncoach 5 months ago

Certainly showing a positive trend on the scientific front.
https://ih.advfn.com/stock-market/NASDAQ/neurosense-therapeutics-NRSN/stock-news/93791685/neurosense-announces-new-positive-data-analysis-fr

runncoach

runncoach 5 months ago

Financing broke the stock for now. Either Biogen news or dead money IMO

runncoach

runncoach 6 months ago

Looks like there will be a data presentation on the sixteenth at a conference. Back in for a gamble at 1.70.

runncoach

runncoach 6 months ago

And there's the money raise at 1.50

runncoach

runncoach 6 months ago

Sold at 2.12. Only update today on the additional biomarker data was talking about peer reviews and conferences. I expected data at least a month ago. I'm concerned they'll raise money before we get any significant data updates. I could be making a mistake but taking profits from .79 so can't be too upset if I do. I'll buy back if it goes lower most likely. GLTA

glenn1919

glenn1919 6 months ago

NRSN..........................https://stockcharts.com/h-sc/ui?s=NRSN&p=W&b=5&g=0&id=p86431144783

Monksdream

Monksdream 6 months ago

runncoach

runncoach 7 months ago

I like Coya a lot as well. I was hoping to see how the Biogen data plays out here and then moving funds there. Hopefully I'll get that chance. I'm not sure COYA's next coming data will be ideal based on the dosage and other trial parameters but could give a great indication to set up a pivotal P3. Lot of bigger money over there. I've got my eyes on them for sure. JMHO

FooBarAndGrill

FooBarAndGrill 7 months ago

Suggest a look at $COYA for ALS.

runncoach

runncoach 7 months ago

Disappointed for the ALS community. Hoping NRSN can provide some hope.
https://finance.yahoo.com/news/amylyx-pharmaceuticals-announces-topline-results-120000695.html?guccounter=1&guce_referrer=YW5kcm9pZC1hcHA6Ly9jb20uZ29vZ2xlLmFuZHJvaWQuZ29vZ2xlcXVpY2tzZWFyY2hib3gv&guce_referrer_sig=AQAAAAM8h3Ee_7hkwe__ixrWmntWVPdxe8WZ1ZpxVn7ZSc5Y_cvU8dUOeH8gNnkII0GDb_rsadt-ieRtojdTcEbDoBluMPdmwoVEaO7k8HMPi6OgMQhLipitwShkj668qEiwBreTeVNkxishXrsTPgOOOMTmvMybqLk3QVA9AiTxt2Bt

runncoach

runncoach 7 months ago

If Biogen results are good then yes. If not then no lol. It's a gamble. I'm not buying at these levels but my cost basis is .795 so I don't have to.

BurgerKing82

BurgerKing82 7 months ago

Is it good time to buy ?

Monksdream

Monksdream 7 months ago

NRSN new 52 week high

glenn1919

glenn1919 7 months ago

NRSN.................................https://stockcharts.com/h-sc/ui?s=NRSN&p=W&b=5&g=0&id=p86431144783

glenn1919

glenn1919 7 months ago

NRSN........................................https://stockcharts.com/h-sc/ui?s=NRSN&p=W&b=5&g=0&id=p86431144783

runncoach

runncoach 7 months ago

I don't know about the biomarker data or any partnership discussions are going but this sure is a lot of volume in a positive fashion the last couple days.

runncoach

runncoach 7 months ago

Updated slide presentation fyi
https://ih.advfn.com/stock-market/NASDAQ/neurosense-therapeutics-NRSN/stock-news/93337353/form-6-k-report-of-foreign-issuer-rules-13a-16

runncoach

runncoach 7 months ago

Looks like additional good news today but the neurofilament results we have been imminently expecting are on track for some time this quarter, which could mean another 5 or 6 weeks. The question remains of how good those results are (or aren't) and if the company raises money before or after. JMHO

Awl416

Awl416 7 months ago

NeuroSense Reports Additional Positive Results from its ALS Phase 2b PARADIGM Trial

Monksdream

Monksdream 7 months ago

BurgerKing82

BurgerKing82 7 months ago

Tues is the 20th I think....Any day.now?...tick tock....

runncoach

runncoach 8 months ago

Looks like the neurofilament light data in collaboration with Biogen isn't quite imminent as today's PR says the coming weeks fyi.

runncoach

runncoach 8 months ago

Looks like the company has regained full Nasdaq compliance

BurgerKing82

BurgerKing82 8 months ago

Could be tomorrow lol

runncoach

runncoach 8 months ago

Not sure the holdup on the neurofilament light data. Though it was supposed to be out in January

rouge Vaughn

rouge Vaughn 8 months ago

yeah looking forward to 2 dollars and up with volume and news

runncoach

runncoach 8 months ago

Quite a run today. Fingers crossed on the new data when released

runncoach

runncoach 8 months ago

Only what you can afford to lose. As risky as any.

BurgerKing82

BurgerKing82 8 months ago

How many shares do folks have in here...I was thinking of getting a few

BurgerKing82

BurgerKing82 8 months ago

Sounds Rational...In 6/22 it did a little more than 3x on 220 million shares...In December it tripled on much smaller volume...Then again in 6/22 ,I guess it could have went a lot higher in pre- mkt/after-hours,maybe that kinda explains the huge volume....idk seems to have potential for a good rip

runncoach

runncoach 8 months ago

I don't honestly know. It's seen huge profit taking every time they've put out positive news. Traders/shorters, who knows. The company needs money to advance and when that's the case you see wild swings. The ball is in Biogen's court it would seem. All depends on the biomarker results we should get at any time.

BurgerKing82

BurgerKing82 8 months ago

hey Runn....What caused Nrsn to dip.between Dec 4th-6th...just curious

BurgerKing82

BurgerKing82 8 months ago

Supposedly they are fully funded into Q2 24'.....As of October 4....There was 22-26 million shares that went buy as the share price declined a bit in December...Maybe it's nothing..."We are optimistic about our mechanisms of action... anticipated in Q4 of 23'".......Still kinda interested

..

BurgerKing82

BurgerKing82 8 months ago

This ticker looked pretty attractive until I noticed it was an Israeli one... Similar to Chinese, Israeli ones more often than not....Is it worth setting that factor aside?

runncoach

runncoach 8 months ago

Potentially yes as long as some of the biomarker data is good. We should find out about that data in the next week or two supposedly to the best of my understanding.

BurgerKing82

BurgerKing82 8 months ago

Is there a positive Catalyst Coming later this month?

rouge Vaughn

rouge Vaughn 10 months ago

you choice is display picture is what is in question, here why are you using that image

rakp

rakp 10 months ago

Why this sudden reversal?

Invest-in-America

Invest-in-America 10 months ago

NRSN: How many time must I post this??? READ IT. I quoted the figures ACCURATELY. In any event, this JUNK STOCK is dead!! Let's all MOVE ON!!

https://www.google.com/search?q=is+als+a+rare+disease&sca_esv=588105669&source=hp&ei=an9vZdOZGevHkPIP2rCN8Aw&iflsig=AO6bgOgAAAAAZW-Nem49qIuR5YltejA1r0lBYMi_4ZKE&oq=is+als+a+ra&gs_lp=Egdnd3Mtd2l6IgtpcyBhbHMgYSByYSoCCAAyBRAAGIAEMgYQABgWGB4yCxAAGIAEGIoFGIYDMgsQABiABBiKBRiGA0iRL1AAWJ4YcAB4AJABAJgB0wKgAY4KqgEHNy4yLjEuMbgBAcgBAPgBAcICCxAAGIAEGLEDGIMBwgIOEC4YgAQYsQMYxwEY0QPCAgsQLhiABBjHARjRA8ICBRAuGIAEwgIREC4YgAQYsQMYgwEYxwEY0QPCAggQLhiABBixA8ICCBAAGIAEGLEDwgILEC4YxwEY0QMYgATCAg4QABiABBiKBRixAxiDAcICCxAuGIAEGLEDGIMBwgIXEC4YgAQYsQMYlwUY3AQY3gQY4ATYAQG6BgYIARABGBQ&sclient=gws-wiz

NeuroSense Therapeutics

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions